Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lisata Therapeutics Inc (LSTA)

Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,982
  • Shares Outstanding, K 8,395
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,840 K
  • EBIT $ -23 M
  • EBITDA $ -24 M
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.76
  • Number of Estimates 2
  • High Estimate -0.73
  • Low Estimate -0.79
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.19 +42.92%
on 12/09/24
3.17 -1.26%
on 12/26/24
+0.29 (+10.21%)
since 11/26/24
3-Month
2.19 +42.92%
on 12/09/24
3.35 -6.57%
on 11/01/24
+0.28 (+9.82%)
since 09/26/24
52-Week
2.19 +42.92%
on 12/09/24
3.83 -18.28%
on 07/16/24
+0.27 (+9.44%)
since 12/26/23

Most Recent Stories

More News
Lisata Therapeutics Completes Patient Enrollment in Phase 1b/2a CENDIFOX Trial for Certepetide in Advanced Solid Tumors

Lisata Therapeutics announces completion of patient enrollment in the CENDIFOX trial for certepetide in advanced solid tumors.Quiver AI SummaryLisata Therapeutics, Inc. has announced the successful completion...

LSTA : 3.13 (+1.13%)
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

LSTA : 3.13 (+1.13%)
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

LSTA : 3.13 (+1.13%)
Lisata Therapeutics Named 'Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough Awards

Lisata Therapeutics receives the ‘Specialized BioTherapeutics Company of the Year’ award for innovative cancer therapies and clinical advancements.Quiver AI SummaryLisata Therapeutics, Inc., a clinical-stage...

LSTA : 3.13 (+1.13%)
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’

LSTA : 3.13 (+1.13%)
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

LSTA : 3.13 (+1.13%)
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...

FOLD : 9.77 (-0.20%)
ESPR : 2.32 (+0.87%)
CRSP : 41.07 (+0.32%)
LSTA : 3.13 (+1.13%)
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

LSTA : 3.13 (+1.13%)
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

LSTA : 3.13 (+1.13%)
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

LSTA : 3.13 (+1.13%)

Business Summary

Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The company's principal product candidate includes LSTA1. Lisata Therapeutics Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 3.33
2nd Resistance Point 3.25
1st Resistance Point 3.19
Last Price 3.13
1st Support Level 3.05
2nd Support Level 2.97
3rd Support Level 2.92

See More

52-Week High 3.83
Fibonacci 61.8% 3.20
Last Price 3.13
Fibonacci 50% 3.01
Fibonacci 38.2% 2.82
52-Week Low 2.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar